{
    "relation": [
        [
            "",
            "Exenatide Once Weekly",
            "Liraglutide Once Daily"
        ],
        [
            "Description",
            "Subcutaneous injection, 2mg, once weekly",
            "Subcutaneous injection, forced titration to 1.8mg, once daily"
        ]
    ],
    "pageTitle": "Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT01029886?sect=X30125&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042986646.29/warc/CC-MAIN-20150728002306-00203-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 852890623,
    "recordOffset": 852875171,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: exenatide once weekly Drug: liraglutide Interventions: Type 2 Diabetes Mellitus Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: February 14, 2012 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Exenatide Once Weekly \u00a0 \u00a0 Liraglutide Once Daily \u00a0 STARTED \u00a0 \u00a0 461 \u00a0 \u00a0 451 \u00a0 Intent to Treat (ITT) \u00a0 \u00a0 461 \u00a0 \u00a0 450 \u00a0 COMPLETED \u00a0 \u00a0 400 \u00a0 \u00a0 391 \u00a0 NOT COMPLETED \u00a0 \u00a0 61 \u00a0 \u00a0 60 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 12 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 25 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}